Activity
The progressive improvement in our country's health system has meant that more and more centers are performing conventional hematopoietic stem cell transplants. That is why our program, in compliance with the usual line of advance of our institution, has directed its efforts towards highly complex transplant programs. Furthermore, in addition to conventional transplants for all types of diseases, we are also developing other lines of care.
Lines of care

AUTOLOGOUS TRANSPLANT FOR UNUSUAL DISEASES
· Autoimmune diseases. Multiple sclerosis, Crohn's disease and lupus erythematosus. We are the only center in Spain taking part in international studies for the treatment of these diseases.
· Plasma cell dyscrasias. Our center is the most experienced center in the country regarding the treatment of light chain diseases or scleromyxedema.

ALLOGENEIC TRANSPLANT FROM AN UNRELATED DONOR
It represents more than half of all allogeneic transplants and the center is responsible for the highest number of these procedures per year in Spain. More and more patients are being treated by umbilical cord transplant due to not being able to locate a compatible volunteer donor.

ALLOGENEIC TRANSPLANT FOR UNCOMMON DISEASES
Lines of transplant care have been developed for patients with diseases that are not curable by any other means, such as idiopathic myelofibrosis, multiple myeloma, aggressive lymphomas, chronic lymphocytic leukemia or paroxysmal nocturnal hemoglobinuria.
The medical team is 100% dedicated to HSCT. As a result, our patients are always seen by the same team of physicians throughout the entire procedure.
Specially trained hospital nurses have extensive experience in the care of these patients with a nurse-to-patient ratio that is never more than 1:2.
Material resources

18 equipped rooms with filtered air that allow ISO Class 8 environmental isolation.

Day hospital specifically for HSCT recipients that is open 7 days a week.

The Apheresis performs a minimum of three procedures a week and provides all the single donor transfusion support that our patients require.

The graft processing, handling and cryopreservation unit is especially equipped to perform all types of cell screening.

The Radiotherapy unit is prepared to administer total body.
Process
|
Case assessment and validation of the indication for transplantation. |
|
|
Individualised evaluation, proposing the most suitable type of transplant for each patient. |
|
|
Search for potential donors in the patient’s circle and in national and international donor banks. |
|
|
Performance of compatibility tests. |
|
|
Extraction of stem cells, with processing, preparation and conservation until transplantation. |
|
|
Performance of the transplant. |
|
|
Post-transplant follow-up of the patient. |
|
|
|
Our results
Results
| |
![]() |
140Stem cell transplants per year |
|
![]() |
|
Patients developing Graft Versus Host Disease |
Survival rate
![]() |
Allogeneic transplant |
![]() |
Autologous transplant |
||||||
![]() |
![]() |
![]() |
![]() |
||||||
| First
year |
For
5
years |
First
year |
For
5
years |
||||||
Time of treatment
| |
![]() |
Average waiting time*4-5 Weeks* Since the search arrives to the register, if the patient has a donor |
|
Estimated time of treatment |
|
· Autologous transplants4-5 months· Allogeneic related donor 8-9 months· Allogeneic unrelated donnor 12 months |
If this information has been interesting for you and you want to know something more, please don't hesitate to contact us. We'll be pleased to listen to you and answer you any doubt.
Blog

Teplizumab, un nuevo tratamiento para retrasar la aparición de la diabetes tipo 1, ahora en barnaclínic+
barnaclínic+ ofrece Teplizumab (Teizeild®), un nuevo tratamiento para la diabetes tipo 1 que permite retrasar la aparición de la enfermedad clínica en determinados pacientes que todavía no presentan síntomas. Esta nueva terapia biológica supone un cambio de paradigma en el abordaje de la diabetes tipo 1, ya que permite actuar sobre el proceso autoinmune responsable […]

Donanemab, un nuevo tratamiento para el Alzheimer ya disponible en barnaclínic+
barnaclínic+ amplía sus opciones terapéuticas para la enfermedad de Alzheimer con Donanemab (Kisunla®), un nuevo tratamiento dirigido a pacientes en fases iniciales de la enfermedad. Este anticuerpo monoclonal actúa sobre las acumulaciones de proteína beta-amiloide en el cerebro y ha demostrado capacidad para ralentizar la progresión del deterioro cognitivo y funcional en determinados pacientes. La […]

barnaclínic+ aborda la hernia discal lumbar y la cirugía endoscópica de columna en el quinto episodio de “Salud (t) Plus”
Tras los anteriores episodios de “Salud (t) Plus”, el podcast de barnaclínic+ que acerca experiencias reales de salud de la mano de pacientes y profesionales, este quinto capítulo se centra en la hernia discal lumbar, una patología de columna que puede provocar dolor lumbar y dolor en la pierna, y en la cirugía endoscópica de […]








